Oropharyngeal Cancer – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Oropharyngeal Cancer – Pipeline Review, H2 2016’, provides an overview of the Oropharyngeal Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Oropharyngeal Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Oropharyngeal Cancer and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Oropharyngeal Cancer

The report reviews pipeline therapeutics for Oropharyngeal Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Oropharyngeal Cancer therapeutics and enlists all their major and minor projects

The report assesses Oropharyngeal Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Oropharyngeal Cancer

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Cancer

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Oropharyngeal Cancer pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Advaxis, Inc.

AstraZeneca Plc

Cell Medica Limited

Genticel S.A.

Immunovaccine Inc

ISA Pharmaceuticals B.V.

Kolltan Pharmaceuticals, Inc.

Merck & Co., Inc.

Novartis AG

PNP Therapeutics, Inc.

Tessa Therapeutics Pte Ltd

VLPbio

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Oropharyngeal Cancer Overview 8

Therapeutics Development 9

Pipeline Products for Oropharyngeal Cancer - Overview 9

Pipeline Products for Oropharyngeal Cancer - Comparative Analysis 10

Oropharyngeal Cancer - Therapeutics under Development by Companies 11

Oropharyngeal Cancer - Therapeutics under Investigation by Universities/Institutes 12

Oropharyngeal Cancer - Pipeline Products Glance 13

Late Stage Products 13

Clinical Stage Products 14

Early Stage Products 15

Oropharyngeal Cancer - Products under Development by Companies 16

Oropharyngeal Cancer - Products under Investigation by Universities/Institutes 17

Oropharyngeal Cancer - Companies Involved in Therapeutics Development 18

Advaxis, Inc. 18

AstraZeneca Plc 19

Cell Medica Limited 20

Genticel S.A. 21

Immunovaccine Inc 22

ISA Pharmaceuticals B.V. 23

Kolltan Pharmaceuticals, Inc. 24

Merck & Co., Inc. 25

Novartis AG 26

PNP Therapeutics, Inc. 27

Tessa Therapeutics Pte Ltd 28

VLPbio 29

Oropharyngeal Cancer - Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

alpelisib - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

axalimogene filolisbac - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

Cellular Immunotherapy for HPV Associated Cancers - Drug Profile 58

Product Description 58

Mechanism Of Action 58

R&D Progress 58

CMD-004 - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

DPXE-7 - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

ganetespib - Drug Profile 61

Product Description 61

Mechanism Of Action 61

R&D Progress 61

gedeptin - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

GTL-001 - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

HNVax - Drug Profile 78

Product Description 78

Mechanism Of Action 78

R&D Progress 78

ISA-101 - Drug Profile 79

Product Description 79

Mechanism Of Action 79

R&D Progress 79

KTN-3379 - Drug Profile 82

Product Description 82

Mechanism Of Action 82

R&D Progress 82

nimotuzumab - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

olaparib - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

pembrolizumab - Drug Profile 99

Product Description 99

Mechanism Of Action 99

R&D Progress 99

PGV-001 - Drug Profile 135

Product Description 135

Mechanism Of Action 135

R&D Progress 135

TT-12 - Drug Profile 136

Product Description 136

Mechanism Of Action 136

R&D Progress 136

Vaccine to Target IL-2 and E7 Protein for Cervical Cancer and Oropharyngeal Cancer - Drug Profile 137

Product Description 137

Mechanism Of Action 137

R&D Progress 137

Oropharyngeal Cancer - Dormant Projects 138

Oropharyngeal Cancer - Product Development Milestones 139

Featured News & Press Releases 139

Aug 11, 2016: Advaxis Announces that Phase 2 Head and Neck Cancer Study with AXAL Advances to Second Stage 139

Apr 18, 2016: Late Breaking Data at AACR Annual Meeting from Advaxis Phase 2 Study of AXAL Highlights Potential of the Company’s Lm Technologyâ„¢ Platform 139

Sep 14, 2015: FDA Awards Grant for Phase 2 Study of Axalimogene Filolisbac in HPV-Associated Head and Neck Cancer 141

Jun 09, 2015: U.S. FDA approves IND application for TT12 HP-VST to begin Phase I trial involving Adoptive T cell therapy on Oropharyngeal Cancer and Cervical Cancer 142

Appendix 143

Methodology 143

Coverage 143

Secondary Research 143

Primary Research 143

Expert Panel Validation 143

Contact Us 143

Disclaimer 144

List of Tables

List of Tables

Number of Products under Development for Oropharyngeal Cancer, H2 2016 9

Number of Products under Development for Oropharyngeal Cancer – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Late Stage Development, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Development, H2 2016 15

Products under Development by Companies, H2 2016 16

Products under Investigation by Universities/Institutes, H2 2016 17

Oropharyngeal Cancer – Pipeline by Advaxis, Inc., H2 2016 18

Oropharyngeal Cancer – Pipeline by AstraZeneca Plc, H2 2016 19

Oropharyngeal Cancer – Pipeline by Cell Medica Limited, H2 2016 20

Oropharyngeal Cancer – Pipeline by Genticel S.A., H2 2016 21

Oropharyngeal Cancer – Pipeline by Immunovaccine Inc, H2 2016 22

Oropharyngeal Cancer – Pipeline by ISA Pharmaceuticals B.V., H2 2016 23

Oropharyngeal Cancer – Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016 24

Oropharyngeal Cancer – Pipeline by Merck & Co., Inc., H2 2016 25

Oropharyngeal Cancer – Pipeline by Novartis AG, H2 2016 26

Oropharyngeal Cancer – Pipeline by PNP Therapeutics, Inc., H2 2016 27

Oropharyngeal Cancer – Pipeline by Tessa Therapeutics Pte Ltd, H2 2016 28

Oropharyngeal Cancer – Pipeline by VLPbio, H2 2016 29

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Stage and Target, H2 2016 32

Number of Products by Stage and Mechanism of Action, H2 2016 34

Number of Products by Stage and Route of Administration, H2 2016 36

Number of Products by Stage and Molecule Type, H2 2016 38

Oropharyngeal Cancer – Dormant Projects, H2 2016 138

List of Figures

List of Figures

Number of Products under Development for Oropharyngeal Cancer, H2 2016 9

Number of Products under Development for Oropharyngeal Cancer – Comparative Analysis, H2 2016 10

Number of Products under Development by Companies, H2 2016 11

Number of Products under Investigation by Universities/Institutes, H2 2016 12

Comparative Analysis by Clinical Stage Development, H2 2016 14

Comparative Analysis by Early Stage Products, H2 2016 15

Assessment by Monotherapy Products, H2 2016 30

Number of Products by Top 10 Targets, H2 2016 31

Number of Products by Stage and Top 10 Targets, H2 2016 31

Number of Products by Mechanism of Actions, H2 2016 33

Number of Products by Stage and Mechanism of Actions, H2 2016 33

Number of Products by Routes of Administration, H2 2016 35

Number of Products by Stage and Routes of Administration, H2 2016 35

Number of Products by Molecule Types, H2 2016 37

Number of Products by Stage and Molecule Types, H2 2016 37

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports